Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $1.1 million.

  • Bicycle Therapeutics' Change in Accured Expenses fell 8829.61% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 15767.87%. This contributed to the annual value of $9.7 million for FY2024, which is 30442.04% up from last year.
  • Bicycle Therapeutics' Change in Accured Expenses amounted to $1.1 million in Q3 2025, which was down 8829.61% from $9.2 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Change in Accured Expenses high stood at $11.5 million for Q2 2023, and its period low was -$8.2 million during Q1 2025.
  • In the last 5 years, Bicycle Therapeutics' Change in Accured Expenses had a median value of $1.3 million in 2021 and averaged $1.5 million.
  • In the last 5 years, Bicycle Therapeutics' Change in Accured Expenses crashed by 30043.1% in 2021 and then surged by 268780.49% in 2022.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Change in Accured Expenses stood at $1.7 million in 2021, then soared by 302.52% to $6.9 million in 2022, then tumbled by 153.68% to -$3.7 million in 2023, then skyrocketed by 201.63% to $3.7 million in 2024, then crashed by 70.07% to $1.1 million in 2025.
  • Its Change in Accured Expenses was $1.1 million in Q3 2025, compared to $9.2 million in Q2 2025 and -$8.2 million in Q1 2025.